Consumers File Class Action Against Fitbit, Inc. Alleging That Fitbit Charge HR and Surge Heart Rate Monitors Do Not Accurately Track Users’ Heart Rates
SAN FRANCISCO--(BUSINESS WIRE)--
Consumers from California, Colorado, and Wisconsin today filed a nationwide class action lawsuit against Fitbit, Inc. (FIT) alleging that Fitbit’s wrist-based “Charge HR” and “Surge” heart rate monitors do not and cannot consistently record accurate heart rates during the intense physical activity for which Fitbit expressly markets the devices in widespread advertising. The suit contends—and expert testing confirms—that the Heart Rate Monitors consistently mis-record heart rates by a significant margin, particularly during intense exercise. Not only are accurate heart readings important for those engaging in fitness, they can be critical tothe health and well-being of people whose medical conditions require them to maintain (or not exceed) a certain heart rate
Much to consumers' chagrin, Fitbit's voluminous advertising on these products does not state or even remotely suggest the technology works only at low or resting heart rates, if at all, and that reported rates from high-intensity activity are wildly inaccurate.
"Fitbit marketed these products through aggressive and widespread advertising to consumers who were not only deceived in the devices' true functionality, but who also were put at a safety risk by trusting the Fitbit Heart Rate Monitors' inaccurate measurements." He added, "Many thousands of consumers paid a premium to get accurate heart rate monitors, and instead got devices that do not work".
CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis
PR Newswire CTI BioPharma Corp.; Baxalta Incorporated1 hour ago
Solar Shares Will Rise, IPOs Won’t; U.S. Judge Tosses Lawyer for Russian Defendants
By Bill Alpert
December 26, 2015
. The steep prices of these treatments will help replace the drug industry’s expiring patents, and are certainly a better way to spend our insurance dollars than the ripoffs of Valeant Pharmaceuticals International (VRX) and Mallinckrodt (MNK).
out for now.
KaloBios CEO Shkreli Puts the Squeeze on Shorts
Shkreli decided not to lend out his shares to shorts, and worse, if he demands delivery on outstanding shares which he has purchased, the stock will go to higher levels, and leaving many people burned.